Results 1 to 10 of about 5,147,229 (341)

ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*

International Journal of Gynecological Cancer, 2023
In 2018, the European Society of Gynecological Oncology (ESGO) jointly with the European Society for Radiotherapy and Oncology (ESTRO) and the European Society of Pathology (ESP) published evidence-based guidelines for the management of patients with ...
D. Cibula, M. Raspollini, F. Planchamp, C. Centeno, Cyrus Chargari, A. Félix, D. Fischerová, Daniela Jahnn-Kuch, F. Joly, C. Kohler, S. Lax, D. Lorusso, U. Mahantshetty, P. Mathevet, R. Naik, Remi A. Nout, A. Oaknin, F. Peccatori, J. Persson, D. Querleu, S.R. Bernabé, M. Schmid, A. Stepanyan, Valentyn Svintsitskyi, K. Tamussino, I. Zapardiel, J. Lindegaard   +26 more
semanticscholar   +1 more source

Cervical cancer screening improvements with self-sampling during the COVID-19 pandemic

eLife, 2023
Background: At the onset of the COVID-19 pandemic cervical screening in the capital region of Sweden was canceled for several months. A series of measures to preserve and improve the cervical screening under the circumstances were instituted, including a
Miriam Elfström, Penelope Grace Gray, Joakim Dillner   +2 more
doaj   +1 more source

NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.

The Journal of the National Comprehensive Cancer Network, 2023
The NCCN Guidelines for Cervical Cancer provide recommendations for all aspects of management for cervical cancer, including the diagnostic workup, staging, pathology, and treatment.
N. Abu-Rustum, C. Yashar, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Susan M. Campos, Junzo Chino, H. Chon, M. Crispens, S. Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Stephanie Gaillard, Robert Giuntoli, Scott Glaser, Jordan Holmes, Brooke E Howitt, Jayanthi Lea, G. Mantia-Smaldone, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Mirna Podoll, Kerry Rodabaugh, Ritu Salani, John Schorge, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, E. Wyse, Nicole R Mcmillian, Shaili Aggarwal, Sara Espinosa   +37 more
semanticscholar   +1 more source

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.

New England Journal of Medicine, 2021
BACKGROUND Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)-positive metastatic or unresectable cervical cancer that has progressed during chemotherapy.
N. Colombo, C. Dubot, D. Lorusso, M. V. Cáceres, K. Hasegawa, R. Shapira-Frommer, K. Tewari, P. Salman, E. Hoyos Usta, E. Yáñez, M. Gümüş, M. Olivera Hurtado de Mendoza, V. Samouëlian, V. Castonguay, A. Arkhipov, S. Toker, Kan Li, S. Keefe, B. Monk   +18 more
semanticscholar   +1 more source

HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK

Pathogens, 2023
Cervical cancer is the fourth most common malignancy in females worldwide, and a leading cause of death in the United Kingdom (UK). The human papillomavirus (HPV) is the strongest risk factor for developing cervical intraepithelial neoplasia and cancer ...
Sunyoung Choi, Ayden Ismail, G. Pappas-Gogos, S. Boussios   +3 more
semanticscholar   +1 more source

Survival with Cemiplimab in Recurrent Cervical Cancer.

New England Journal of Medicine, 2022
BACKGROUND Patients with recurrent cervical cancer have a poor prognosis. Cemiplimab, the fully human programmed cell death 1 (PD-1)-blocking antibody approved to treat lung and skin cancers, has been shown to have preliminary clinical activity in this ...
K. Tewari, B. Monk, I. Vergote, A. Miller, A. C. de Melo, H. Kim, Y. M. Kim, A. Lisyanskaya, V. Samouëlian, D. Lorusso, F. Damian, Chih-Long Chang, Evgeniy Gotovkin, S. Takahashi, D. Ramone, J. Pikiel, B. Maćkowiak-Matejczyk, E. G. Guerra Alía, N. Colombo, Y. Makarova, D. Rischin, S. Lheureux, K. Hasegawa, K. Fujiwara, Jingjin Li, Shaheda Jamil, V. Janković, Chieh-I. Chen, F. Seebach, D. Weinreich, G. Yancopoulos, I. Lowy, M. Mathias, M. Fury, A. Oaknin   +34 more
semanticscholar   +1 more source

Carcinogenesis and management of human papillomavirus-associated cervical cancer

International Journal of Clinical Oncology, 2023
Approximately 95% of cervical cancer are caused by human papillomavirus (HPV) infection. Although it is estimated that HPV-associated cervical cancer will decrease with the widespread use of HPV vaccine, it may take time for HPV-associated cervical ...
M. Kusakabe, Ayumi Taguchi, K. Sone, M. Mori, Y. Osuga   +4 more
semanticscholar   +1 more source

Cancer statistics, 2023

Ca, 2023
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population‐based cancer occurrence and outcomes using incidence data collected by central cancer ...
R. Siegel, K. D. Miller, N. S. Wagle, A. Jemal   +3 more
semanticscholar   +1 more source

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Ca, 2021
This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer.
H. Sung, J. Ferlay, R. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray   +6 more
semanticscholar   +1 more source

Hybrid Model for Detection of Cervical Cancer Using Causal Analysis and Machine Learning Techniques

Computational and Mathematical Methods in Medicine, 2022
Cervical cancer has become the third most common form of cancer in the in-universe, after the widespread breast cancer. Human papillomavirus risk of infection is linked to the majority of cancer cases.
U. Lilhore, M. Poongodi, Amandeep Kaur, Sarita Simaiya, Abeer D. Algarni, H. Elmannai, V. Vijayakumar, Godwin Brown Tunze, Mounir Hamdi   +8 more
semanticscholar   +1 more source